The Institute of Molecular Biology (IMB) is a modern research centre, which is funded by the Boehringer Ingelheim Foundation – a non-profit organisation with a long tradition in funding outstanding research in the fields of medicine, biology, chemistry and pharmacy – as well as by the State of Rhineland-Palatinate.
Starting in autumn 2020, the Boehringer Ingelheim foundation will contribute €54 million, the state of Rhineland Palatinate €52 million. This second round of financing secures IMB's core funding until mid-2027. It follows the generous donation of €100 million by the Boehringer Ingelheim foundation in 2010, which provided core funding for IMB through the period 2010 to 2020. IMB is housed in a state-of-the-art research building that was funded by the state of Rhineland Palatinate with €50 million in 2010.
This generous core funding ensures that our scientists have all it takes to compete at the very forefront of science and allows our groups to embark on long-term innovative projects. IMB is headed by the Executive Director, Christof Niehrs.
Our aim is to conduct basic and applied research in developmental biology, epigenetics, genome stability and related biomedical areas. IMB is a non-profit company, but it operates like an academic research centre.
Hierarchies at IMB are deliberately flat, and our research groups enjoy full independence. The working language at IMB is English and we are proud of our international and innovative atmosphere. We are a young research centre with a clear focus on excellence. We have over 200 staff and 17 groups investigating questions at the cutting edge of biomedicine. As such, we offer excellent opportunities for young, ambitious scientists to work in an international and dynamic research environment in the heart of Europe.
To download a PDF of the current IMB flyer, please click here: PDF (8 MB file)